Alerta

Compositions and Methods for Modulation of Immune Responses

Resumen de: US20260227408A1

0000 The disclosure provides, in various embodiments, compositions, such as polypeptides, polynucleotides, gene editing system, small molecules, vectors or host cells, that comprises and/or modulate expression or activity of immune regulation-associated proteins. The disclosure also provides, in various embodiments, methods of treating aging, senescence, fibrosis, autoimmunity, cancer, an infection, and/or an immunological disease using an agent that comprises and/or modulates expression or activity of an immune regulation-associated protein and methods of identifying said agent.

COMPOSITIONS INCLUDING ANTI-WT-1 ANTIBODIES & ANTIGEN BINDING FRAGMENTS AND USES THEREOF

Resumen de: US20260226173A1

The present technology relates generally to compositions that specifically recognize and bind to a WT-1 peptide complexed with a major histocompatibility antigen (e.g., HL A-A*02). The compositions of the present technology are useful in methods for treating WT-1-associated diseases (e.g., cancers) in a subject in need thereof.

ENHANCEMENT OF SYNAPTOGENESIS BY ACTIVATION OF TENEURINS

Resumen de: US20260224661A1

Methods are provided for enhancing synaptogenesis. It is shown herein that the receptor for the circulating factor SPARCL1 (secreted protein acidic and rich in cysteine-like protein) are teneurin proteins (Tenm1-4). The binding site for SPARCL1 is localized to domain 3, which specifically binds to the C terminal domain of SPARCL1 (SPARCL1-C). Contacting neuronal cells expressing a teneurin protein with SPARC is sufficient to increase synapse formation on the neuronal cells.

BIOMARKERS RELATED TO IMMUNOTHERAPY EFFICACY

Resumen de: US20260224626A1

0000 The disclosure relates to methods for predicting a likelihood of a relapse to a cancer in a patient following treatment of the patient with an immunotherapy product, and methods for improving efficacy of an immunotherapy product for a patient with a likelihood of a relapse to a cancer following treatment with an immunotherapy product.

Methods of Treating Neurological Disorders with Anti-Abeta Antibodies

Resumen de: US20260226143A1

0000 Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.

METHOD FOR IDENTIFYING A MULTI-PARAMETER PHENOTYPE OF MICROBIOTA

Resumen de: US20260227396A1

0000 A method for identifying a multi-parameter phenotype of microbiota. The method includes (i) providing a sample including microbiota, (ii) labeling the microbiota with multiple labels, each of which binds a phenotypic parameter of the microbiota, (iii) detecting an intensity of the labelled phenotypic parameters of single cells of the microbiota by flow cytometry, and (iv) segmenting the single cells into bins based on the intensities of detected phenotypic parameters, wherein the distribution of single cells in bins represents a multi-parameter phenotype of said microbiota. Also described is a system for identifying a multi-parameter phenotype of intestinal microbiota, a kit for identifying a multi-parameter phenotype of intestinal microbiota and methods for diagnosing a medical condition associated with microbiota, for example an inflammatory condition, such as an inflammatory bowel disease, in a subject.

ANTIBODIES FOR TREATING NEUROLOGICAL AND NEUROVASCULAR DISORDERS

Resumen de: US20260226177A1

0000 The present disclosure provides humanized anti-GluN1 receptor antibodies and antigen-binding fragments or derivatives thereof, which are effective in inhibiting the deleterious effects of tissue-type plasminogen activator (t-PA) mediated by N-methyl-D-aspartate (NMDA) receptors, as well as pharmaceutical compositions and medical uses thereof, particularly for the treatment of neurological, neurovascular or neurodegenerative disorders, such as stroke, multiple sclerosis, Parkinson's disease, and others.

IDENTIFICATION OF THE PROTEINS ELASTASE 3B AND IGKAPPA CHAIN AS FECAL BIOMARKERS FOR THE DIAGNOSIS AND PROGNOSIS OF ALZHEIMER' S DISEASE

Resumen de: WO2026163093A1

Two proteins, Elastase 3B and igKappa chain, are identified as biomarkers for the diagnosis and prognosis of Alzheimer's disease (Alzheimer Disease, AD). These proteins can be detected in fecal samples from subjects affected by this pathology and exhibit a statistically significant variation in samples from AD subjects compared with the levels detected in a healthy reference sample, thereby making it possible to provide both diagnosis and prognosis of AD in a simple and non-invasive manner, in particular, Elastase 3B and igKappa chain emerge as complementary biomarkers with opposite and progressive modulation. Specifically, Elastase 3B decreases in all phases of the pathology, whereas igKappa chain shows a progressive increase that reflects the progression of AD. The combined use of these two proteins as complementary biomarkers is therefore applicable for the early diagnosis and prognosis of AD. To achieve this objective, a strategy based on the use of a preclinical model was adopted, namely the triple-transgenic murine model (3xTg-AD), which mimics the AD pathology observed in humans and reproduces its characteristics and different stages. Based on the premise that the results obtained may also be predictive for humans, the use > of the murine model offers an important advantage, namely the possibility of collecting samples to be analyzed at precise time points, thereby allowing the study of the pathology in its different stages, from the asymptomatic phase to the early sym

METHODS PERTAINING TO NEURODEGENERATIVE DISEASE

Resumen de: WO2026165150A2

Disclosed herein are methods pertaining to analyzing a biological sample from a subject for a neurodegenerative disease. In one aspect, the disclosure relates to a method for analyzing a biological sample from a subject for a neurodegenerative disease. This method involves determining a ratio of pTau217 to BD-Tau present in a biological sample obtained from a subject and diagnosing the subject as (i) having Alzheimer's disease when the ratio of pTau217 to BD-Tau in the sample is a at least a first predetermined value; (ii) a healthy subject (no neurodegenerative disease) when the ratio of pTau217 to BD-Tau in the sample is below a second predetermined value; and/or (iii) having a disease other than Alzheimer's disease associated with high levels of pTau217 when the ratio of pTau217 to BD-Tau in the sample is between the second predetermined value and the first predetermined value.

METHOD FOR MODULATING SPLICING OF SIRTUIN 1

Resumen de: WO2026165098A1

A method for modulating splicing of Sirtuin 1 includes administering or adding to a subject 3-methyl-1-phenyl-2-pyrazolin-5-one, a physiologically acceptable salt thereof, a hydrate thereof, and/or a solvate thereof.

METHODS OF USING KISSPEPTIN OR KISSPEPTIN ANALOGS OR PHARMACEUTICAL COMPOSITIONS

Resumen de: WO2026165222A2

The invention features methods of treating a subject having a disorder by administering to the subject a kisspeptin analog or a pharmaceutically acceptable salt thereof, kisspeptin-10 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof. Disorders that may be treated by the kisspeptin analogs or a pharmaceutically acceptable salt thereof, kisspeptin-10 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition include reproductive disorders, hypoactive sexual arousal disorder, respiratory diseases, metabolic disorders, liver disorders, bone disorders, VMS, neurodegenerative disorders, and sequelae of neurotropic viruses. Also provided herein are methods of identifying a subject as having congenital hypogonadotropic hypogonadism (HH) and methods of determining whether a patient having a disorder is likely to respond to a therapy comprising a therapeutically effective amount of a kisspeptin analog or a pharmaceutically acceptable salt thereof, kisspeptin-10 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

CORRECTING NOVA-ASSOCIATED HUMAN NEUROLOGICAL DISORDERS

Resumen de: WO2026165496A1

The invention relates to methods of altering expression or activity of NOVA 1 or NOVA2. The invention provides anti-microRNA molecules directed against miRNA binding sites on untranslated regions that serve to redirect RNA translation, including acting as a competitor for miRNA binding on targets, including NOVA1 and NOVA2. The invention provides methods for inhibiting microRNAs directed to NOVA1 or NOVA 1 in an animal by administering one of more anti-microRNA molecule specific therefore. Methods of alleviating one or more disease or condition, including altering or modulating vocalization, language dysfunction, autism (including non-verbal autism), microencephaly, seizures, developmental delay or cancer are provided. In accordance with such methods, NOVA1 or NOVA2 expression or activity is modulated to result in alleviation of one or more disease or condition.

CAPTURE OF MISFOLDED PROTEIN AGGREGATES BY BEADS BOUND TO AN AMYLOID-BINDING DYE.

Resumen de: WO2026165436A1

Methods are provided for the capture of misfolded protein aggregates by beads bound to an amyloid-binding dye. Methods for using the misfolded protein aggregate-bound beads are also provided.

DEVICE FOR MEASURING LIQUID VISCOSITY

Resumen de: WO2026162924A1

The disclosure relates to a device for measuring liquid viscosity wherein said device comprises a concave reservoir configured to hold a volume of liquid and one or more wells extending from an opening disposed at the base of said reservoir, wherein said base comprises an aperture having dimensions configured to retain within said well a liquid having a viscosity at or above a specific threshold viscosity by surface tension, but permit a liquid having a viscosity below said specific threshold viscosity to pass through said well under the influence of gravity. Further, the invention also relates to a method for assessing liquid viscosity using the abovementioned device, particularly in individuals suffering from dysphagia in healthcare facilities, such as care homes.

CALIBRATOR DIPEPTIDE FOR PHOSPHORYLATED TAU (P-TAU) 217 IMMUNOASSAYS

Resumen de: WO2026164954A1

The presently claimed and described technology provides a calibrator dipeptide for use in immunoassay methods for detecting phosphorylated tau (p-tau)217.

C-PEPTIDE-INSULIN FORMULATION AND METHOD FOR USE OF SAME

Resumen de: WO2026161967A1

A pharmaceutical composition co-formulating insulin and C-peptide for simultaneous delivery to restore physiological coordination is described. The invention is based on the discovery, validated by advanced artificial intelligence (AI) modeling, that C-peptide acts on at least three distinct receptors (the Insulin Receptor, GPR146, and RXFP1) to potentiate insulin signaling, terminate pro-metabolic signals that lead to hypercortisolemia and dyslipidemia, and activate anti-fibrotic pathways. This approach is supported by a model of an integrated hormonal network where the relaxin, C-peptide, and cortisol systems are interwoven through central neuroendocrine modulation, direct molecular crosstalk, and metabolic convergence. These coordinated mechanisms provide comprehensive diabetes management beyond glucose control. The co-formulation is approximately 7-fold more mass-efficient than insulin monotherapy. Furthermore, the invention provides a dual-mechanism neuroprotective therapy for Alzheimer's disease by inhibiting amyloid-beta production in neurons and promoting its clearance by microglia via a novel neuro-immune pathway.

EXCREMENT ANALYSIS APPARATUS, ANALYSIS SYSTEM, SERVER APPARATUS, ANALYSIS METHOD, AND NON-TRANSITORY COMPUTER-READABLE MEDIUM

Resumen de: US20260224206A1

An excrement analysis apparatus includes an inputter, a memory, a first analyzer, and a second analyzer. The inputter inputs imaging data captured by an image capture apparatus installed in such a way as to include, in a capturing range, an excretion range of excrement in a toilet bowl of a toilet. The memory temporarily holds the imaging data input by the inputter. The first analyzer analyzes first analysis target data being the imaging data input by the inputter, and outputs notification information to an observer who observes a user of the toilet. The second analyzer analyzes second analysis target data being the imaging data that is input by the inputter and temporarily held by the memory, and outputs detailed information indicating a content of excretion.

脳脊髄液に含まれるＨｅｘ４の定量法

Resumen de: WO2021039644A1

The present invention addresses the problem of providing a method for quantifying Hex4, lyso-GM1, Fuc-GlcNAc-Asn, or lyso-sulfataide in a brain. The present invention relates to a method for quantifying Hex4, lyso-GM1, Fuc-GlcNAc-Asn, or lyso-sulfataide included in a cerebrospinal fluid, the method comprising: a step for adding an internal standard substance to a solution containing the cerebrospinal fluid; a step for subjecting the solution, which contains the cerebrospinal fluid and to which the internal standard substance is added, to liquid chromatography to obtain an effluent; and a step for providing the effluent for mass spectrometry.

MULTIPLEXED ASSAY AND METHODS OF USE THEREOF

Resumen de: WO2020146652A1

The present disclosure provides methods for blood-based examination useful to identify subjects with Aβ amyloidosis and/or to identify subjects who should or should not undergo further testing or treatment for Aβ amyloidosis, as well as methods for treating subjects diagnosed with Aβ amyloidosis by the methods disclosed herein.

METHOD AND SYSTEM FOR IDENTIFYING BIOMARKERS OF A HEALTH CONDITION

Resumen de: EP4786977A1

A method for identifying biomarkers of a health condition, comprising: providing a first neuronal circuit with neuronal cells from a first individual organism on a multi-electrode array, applying stimuli to the circuit, obtaining electrophysiological recordings, deriving cell-level and/or circuit-level features from the recordings, associating derived features with presence or absence of the health condition, comparing associated data with reference data, and determining if reference features or derived features are biomarkers for the condition.

MATRIX FOR EXTRACORPOREAL REMOVAL OF MT-DNA FROM BLOOD

Resumen de: EP4786984A1

The invention relates to a matrix configured for use in an extracorporeal blood treatment device, wherein the matrix comprises a solid substrate, to which an agent is immobilized, wherein said agent specifically binds mitochondrial DNA (mtDNA) in the blood or blood plasma of a subject. The invention also relates to methods for preparing the matrix according to the present invention, wherein the oligonucleotide and/or the polypeptide is immobilized on the solid substrate of the matrix by covalent coupling, preferably by crosslinking. The invention further relates to a blood treatment device configured to remove mtDNA from the blood or blood plasma of a person in need thereof in an extracorporeal blood circuit, wherein the device comprises a matrix according to the present invention. The invention further relates to an extracorporeal blood circuit comprising a blood treatment device according to the present invention, wherein the extracorporeal blood circuit comprises means for transporting blood or blood plasma from a patient's vascular system to the blood treatment device at a defined flow rate and means for returning the treated blood or blood plasma back to the patient.

COMBINATION OF OBEFAZIMOD AND ITS DERIVATIVES WITH A TNF ALPHA-INHIBITOR

Resumen de: EP4785940A1

0001 The present invention relates to pharmaceutical combinations, pharmaceutical compositions, kits comprising a compound of formula (I), a pharmaceutically acceptable salt thereof, a prodrug thereof, or a metabolite thereof, and a TNFα-inhibitor. The present invention also relates to said pharmaceutical combinations for use in the treatment of an inflammatory disease, disorder, or condition. The compound of formula (I) has the following formula:

一种水产品组胺的快速检测试纸条的制备及检测方法

Resumen de: CN122506155A

该水产品组胺的快速检测试纸条制备及检测方法，通过测流层析的方式，以适配体为特异性识别元件，使用价格适宜、易于合成的DNA链作为基本元件解决了现有水产品组胺的检测方法存有的操作过程繁琐、特异性和稳定性弱、成本高昂的问题，特别适合水产品组胺检测使用的需要。

基于LTF的PASC相关心血管系统症状风险评估应用

Resumen de: CN122503499A

本发明涉及生物医药技术领域，尤其是涉及基于LTF的PASC相关心血管系统症状风险评估应用。本发明提供了一种以LTF为核心分子标志物的风险评估体系，该体系能够在常规检测手段难以提供充分解释的情况下，为PASC相关心血管系统症状风险评估提供客观、可量化的分子层面参考依据。

一种便携式等离子增强/比率荧光传感器的制备方法及其在β-淀粉样蛋白可视化检测中的应用

Nº publicación: CN122506168A 04/08/2026

Solicitante:

南京师范大学

Resumen de: CN122506168A

本发明公开了一种基于金纳米颗粒的等离子增强荧光偶联适配体比率传感器的制备方法及其在淀粉样蛋白可视化检测中的应用。本发明制备金纳米颗粒，通过加入EDC/NHS将金纳米颗粒固定在氨基化的酶标板上；使两端分别修饰氨基和巯基的β‑淀粉样蛋白适配体形成Au‑S键接枝至金纳米颗粒修饰的酶标板；加入EDC/NHS将孟加拉玫瑰通过酰胺键接枝至金纳米颗粒上的适配体上得到以等离子体增强荧光偶联适配体作为响应荧光探针，以9‑蒽甲酸作为参比荧光制得等离子增强/比率荧光探针传感器。本发明制备的等离子增强/比率荧光探针传感器的稳定性好，实现便携式、超灵敏和特异性的β‑淀粉样蛋白可视化定量检测。